Biogen ALS Drug Receives Backing of FDA Panel in 9-0 Vote, FDA Says Tofersen Likely to Predict Benefit
Biogen (BIIB) ALS Drug Receives Backing of FDA Panel in 9-0 Vote, FDA Says Tofersen Likely to Predict Benefit
Strong Buy
or
Biogen News & Analysis
-
-
Analysts positive on Biogen after FDA posts docs ahead of advisory panel for Tofersen
By Davit Kirakosyan FDA posted documents yesterday ahead of the advisory panel for Biogen's (NASDAQ:BIIB) Tofersen for ALS. Needham believes these documents strike a favorable tone and the...
-
FDA Posts Documents Ahead of Advisory Panel for Biogen's Tofersen for ALS
FDA Posts Documents Ahead of Advisory Panel for Biogen's (BIIB) Tofersen for ALS...
-
Eisai, Biogen Alzheimer's Leqembi To Get Some Va Coverage - Bloomberg
Eisai, Biogen (NASDAQ:BIIB) Alzheimer's Leqembi To Get Some Va Coverage - Bloomberg
-
Biogen Announces Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Board of Directors
Biogen Inc. (NASDAQ:BIIB) today announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company’s 2023 Annual...
-
Eisai, Biogen announced FDA accepts sBLA for LEQEMBI
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's supplemental Biologics License Application (sBLA) for...
-
Biogen tops Q4 analyst estimate, guidance mixed
By Senad Karaahmetovic Biogen (NASDAQ:BIIB) reported better-than-expected fourth-quarter results to see its shares trade modestly higher in pre-market Wednesday. The company reported Q4...
-
Biogen Tops Q4 EPS by 57c, Offers Guidance
Biogen (NASDAQ:BIIB) reported Q4 EPS of $4.05, $0.57 better than the analyst estimate of $3.48. Revenue for the quarter came in at $2.54 billion versus the consensus estimate of $2.44...
-
Biogen earnings beat by $0.57, revenue topped estimates
Investing.com - Biogen (NASDAQ: BIIB) reported fourth quarter EPS of $4.05, $0.57 better than the analyst estimate of $3.48. Revenue for the quarter came in at $2.54B versus the consensus...
-
Flying objects, Adani, EU recession, U.S. CPI, Crude - what's moving markets
By Peter Nurse Investing.com -- The U.S. Air Force continues to shoot down unexplained flying objects over North America, while beleaguered Indian conglomerate Adani plans to reduce capital...
-
Biogen gains as analysts reflect positively on Leqembi's approval, pricing
By Senad Karaahmetovic On Friday, the United States Food and Drug Administration (FDA) officially approved Leqembi, a new drug developed by Biogen (NASDAQ:BIIB) and Japan-based Eisai...
-
Eisai, Biogen Alzheimer drug granted FDA accelerated approval
By Sam Boughedda On Friday, the U.S. Food and Drug Administration approved lecanemab, the Alzheimer's drug developed by Eisai Co (OTC:ESALY) and Biogen (NASDAQ:BIIB) for patients in the...
-
For Lecanemab, a $25k to $30k annual price 'could still be appropriate' - Wells Fargo
By Sam Boughedda Wells Fargo analysts said in a note on biotechnology stocks on Friday that for Biogen (NASDAQ:BIIB), a $25,000 to $30,000 annual price could still be appropriate for...
-
Analysts impressed by Biogen after full data on Alzheimer's drug Lecanemab
By Senad Karaahmetovic Biogen (NASDAQ:BIIB) yesterday presented detailed results from the Ph3 Clarity AD confirmatory trial. According to the company, Lecanemab "reduced markers of amyloid...
-
Biogen stock falls on Alzheimer's drug trial death reports
By Sam Boughedda Biogen (NASDAQ:BIIB) shares dipped Monday after a report by Science.org stated that a woman participating in a trial of experimental Alzheimer's treatment lecanemab had...
-
S&P 500 advances as Fed officials signal slower hikes, but higher for longer rates
By Yasin Ebrahim Investing.com -- The S&P 500 inched higher Monday after swinging between gains and losses as investors digested remarks from the Federal Reserve officials insisting further...
-
Biogen new CEO could be 'just what BIIB needs'
By Sam Boughedda Biogen (NASDAQ:BIIB) announced that the former CEO of Sanofi (NASDAQ:SNY), Christopher Viehbacher, will take over as its President, CEO, and member of the Board of...
-
Biogen Poised to Address Early Alzheimer's Market From 2023 - Goldman Sachs
By Sam Boughedda Goldman Sachs analysts upgraded Biogen (NASDAQ:BIIB) to Buy from Neutral, raising the firm's price target on the stock to $370 from $271 in a note Wednesday. It is the sixth...
-
Biogen earnings, Revenue beat in Q3
Investing.com - Biogen (NASDAQ:BIIB) reported on Tuesday third quarter {{erl-6487||earnings that beat analysts' forecasts and revenue that topped expectations. Biogen announced earnings...
-
Biogen Tops Q3 EPS by 63c, Raises Guidance
Biogen (BIIB) reported Q3 EPS of $4.77, $0.63 better than the analyst estimate of $4.14. Revenue for the quarter came in at $2.51 billion versus the consensus estimate of $2.47...
-
Biogen Risk/Reward is Upside Biased - Stifel
By Sam Boughedda Biogen (NASDAQ:BIIB) shares were upgraded to Buy from Hold, with the price target raised to $299 from $223 per share by Stifel analysts on Thursday. The analysts said the...
-
Analysts Discuss Implications for Eli Lilly After Biogen's Big Win
By Senad Karaahmetovic Shares of Eli Lilly (NYSE:LLY) are up almost 8% in sympathy with Biogen (NASDAQ:BIIB), which trades about 54% higher in pre-open Wednesday. Biogen announced that its...
-
Biogen Surges After 'Best-Case' Alzheimer's Drug Trial Results; Stock Earns Several Upgrades
By Senad Karaahmetovic Shares of Biogen (NASDAQ:BIIB) are trading sharply higher in pre-market Wednesday after the company announced positive topline results for its experimental Alzheimer’s...
-
'Must Win,' 'Make or Break': Biogen Could Stage a Massive Rally on Positive Clarity-AD Results - Analyst
By Senad Karaahmetovic Ahead of the expected data from the CLARITY-AD pivotal trial of lecanemab in Alzheimer's disease, a BMO analyst weighed in on potential outcomes and what they would...
-
Biogen Could Become a Strategic Asset - Jefferies
By Sam Boughedda A Jefferies equity analyst told investors in a note on Monday that they believe Biogen (NASDAQ:BIIB) could become a strategic asset. In a note focused on the Phase III...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
